{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:08:38Z","timestamp":1777388918486,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00280-018-3531-x","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:38:08Z","timestamp":1517272688000},"page":"549-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-8347","authenticated-orcid":false,"given":"Souichi","family":"Yanamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitomu","family":"Kioi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaaki","family":"Kirita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tanzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Shibahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihide","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Hamakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingo","family":"Kusukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwai","family":"Tohnai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"3531_CR1","first-page":"54","volume-title":"World cancer report 2014","author":"F Bray","year":"2014","unstructured":"Bray F (2014) Transitions in human development and the global cancer burden. In: Stewart BW, Wild CP (eds) World cancer report 2014. International Agency for Research on Cancer, Lyon, pp\u00a054\u201368"},{"key":"3531_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","volume":"350","author":"J Bernier","year":"2004","unstructured":"Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lef\u00e8bvre J, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Eng J Med 350:1945\u20131952","journal-title":"N Eng J Med"},{"key":"3531_CR3","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","volume":"350","author":"JS Cooper","year":"2004","unstructured":"Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KSC, Schultz CJ, Lee N, Fu KK (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Eng J Med 350:1937\u20131944","journal-title":"N Eng J Med"},{"key":"3531_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/hed.20279","volume":"27","author":"JB Bernier","year":"2005","unstructured":"Bernier JB, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL (2005) Defining risk level in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:843\u2013850","journal-title":"Head Neck"},{"key":"3531_CR5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ijrobp.2012.05.008","volume":"84","author":"JS Cooper","year":"2012","unstructured":"Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK (2012) Long-term follow-up of the RTOG 9501\/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Phys 84:1198\u20131205","journal-title":"Int J Radiat Oncol Phys"},{"key":"3531_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1586\/14737140.8.3.375","volume":"8","author":"PM Specenier","year":"2008","unstructured":"Specenier PM, Vermorken JB (2008) Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8:375\u2013391","journal-title":"Expert Rev Anticancer Ther"},{"key":"3531_CR7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijrobp.2007.09.058","volume":"71","author":"J Kao","year":"2008","unstructured":"Kao J, Lavaf A, Teng MS, Huang D, Genden EM (2008) Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: An analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys 71:362\u2013370","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3531_CR8","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","volume":"15","author":"PH O\u2019Donnell","year":"2009","unstructured":"O\u2019Donnell PH, Dolan ME (2009) Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 15:4806\u20134814","journal-title":"Clin Cancer Res"},{"key":"3531_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/jjco\/hys128","volume":"42","author":"N Kiyota","year":"2012","unstructured":"Kiyota N, Tahara M, Okano S, Kawashima M, Matsuura K, Onozawa Y, Nibu K, Hayashi R, Yoshimura K, Ohtsu A (2012) Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 42:927\u2013933","journal-title":"Jpn J Clin Oncol"},{"key":"3531_CR10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupssol D, Peyrade F, Benasso M, Vynnychenko I, de Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med 359:1116\u20131127","journal-title":"N Eng J Med"},{"key":"3531_CR11","unstructured":"National Comprehensive Cancer Network (2017) Clinical practice guidelines in oncology. Head and neck cancers. Version 2. 2017. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf\/\n                    \n                  . Accessed 26 Aug 2017"},{"key":"3531_CR12","doi-asserted-by":"publisher","first-page":"v184","DOI":"10.1093\/annonc\/mdq185","volume":"21","author":"V Gr\u00e9goire","year":"2010","unstructured":"Gr\u00e9goire V, Lefebvre JL, Lictra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v184\u2013186","journal-title":"Ann Oncol"},{"key":"3531_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3531_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/hed.23227","volume":"36","author":"AS Ho","year":"2014","unstructured":"Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LG (2014) Decision making in the management of recurrent head and neck cancer. Head Neck 36:144\u2013151","journal-title":"Head Neck"},{"key":"3531_CR15","doi-asserted-by":"publisher","first-page":"e86697","DOI":"10.1371\/journal.pone.0086697","volume":"9","author":"RA Mello de","year":"2014","unstructured":"de Mello RA, Ger\u00f3s S, Alves MP, Moreira F, Avezedo I, Dinis J (2014) Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehends European cancer institution. PloS One 9:e86697","journal-title":"PloS One"},{"key":"3531_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/jjco\/hyt034","volume":"43","author":"T Yoshino","year":"2013","unstructured":"Yoshino T, Hasegawa Y, Takahashi S, Monden N, Homma A, Okami K, Onozawa Y, Fujii M, Taguchi T, de Blas B, Beier F, Tahara M (2013) Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol 43:524\u2013531","journal-title":"Jpn J Clin Oncol"},{"key":"3531_CR17","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/hed.23707","volume":"37","author":"Y Guo","year":"2015","unstructured":"Guo Y, Shi M, Yang A, Feng J, Zhu X, Choi YJ, Hu G, Pan J, Hu C, Luo R, Zhang Y, Zhou L, Cheng Y, Lupfert C, Cai J, Shi Y (2015) Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: results of an open-label, single-arm, multicenter trial. Head Neck 37:1081\u20131087","journal-title":"Head Neck"},{"key":"3531_CR18","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1177\/0194599815580980","volume":"152","author":"T Hasegawa","year":"2015","unstructured":"Hasegawa T, Tanakura M, Takeda D, Sakakibara A, Akashi M, Minamikawa T, Komori T (2015) Risk factors associated with distant metastasis in patients with oral squamous cell carcinoma. Otolaryngol Head Neck Surg 152:1053\u20131060","journal-title":"Otolaryngol Head Neck Surg"},{"key":"3531_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.oooo.2015.11.022","volume":"121","author":"Y Sakamoto","year":"2016","unstructured":"Sakamoto Y, Matsushita Y, Yamada SI, Yanamoto S, Shiraishi T, Asahina I, Umeda M (2016) Risk factors of distant metastasis in patients with squamous cell carcinoma of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol 121:474\u2013480","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"3531_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharynxgeal cancer. N Eng J Med 363:24\u201335","journal-title":"N Eng J Med"},{"key":"3531_CR21","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1200\/JCO.2013.54.5228","volume":"32","author":"CH Chung","year":"2014","unstructured":"Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT (2014) p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 32:3920\u20133938","journal-title":"J Clin Oncol"},{"key":"3531_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/annonc\/mdt574","volume":"25","author":"JB Vermorken","year":"2014","unstructured":"Vermorken JB, Psyrri A, Mesia R, Peyrade F, Beier F, de Blas B, Celik I, Lictra L (2014) Impact of tumor HPV status on outcome in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 25:801\u2013807","journal-title":"Ann Oncol"},{"key":"3531_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12885-016-2064-0","volume":"16","author":"D Soulieres","year":"2016","unstructured":"Soulieres D, Aguilar JL, Chen E, Misiukiewicz K, Ernst S, Lee HJ, Bryant K, He S, Obasaju CK, Chang SC, Chin S, Adkins D (2016) Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. BMC Cancer 16:19","journal-title":"BMC Cancer"},{"key":"3531_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1349-7006.2001.tb01100.x","volume":"92","author":"K Yamaguchi","year":"2001","unstructured":"Yamaguchi K, Arai Y, Kanda Y, Akagi K (2001) Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn J Cancer Res 92:337\u2013342","journal-title":"Jpn J Cancer Res"},{"key":"3531_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1007\/s10038-007-0186-6","volume":"52","author":"K Maekawa","year":"2007","unstructured":"Maekawa K, Saeki M, Saito Y, Ozawa S, Kurose K, Kaniwa N, Kawamoto M, Kamatani N, Kato K, Hamaguchi T, Yamada Y, Shirao K, Shimada Y, Muto M, Doi T, Ohtsu A, Yoshida T, Matsumura Y, Saijo N, Sawada J (2007) Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 52:804\u2013819","journal-title":"J Hum Genet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3531-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3531-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3531-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T20:24:51Z","timestamp":1548793491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3531-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["3531"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3531-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"22 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The need for informed consent was waived by the Institutional Review Boards of each participating institution because of the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}